Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE)

Health Technology Assessment

Volumn 14, Issue 1, 2010, Pages 1-158

  Turnbull, L W ^a   Brown, S R ^b   Olivier, C ^b   Harvey, I ^a   Brown, J ^b   Drew, P ^c   Hanby, A ^d   Manca, A ^e   Napp, V ^b   Sculpher, M ^e   Walker, L G ^a   Walker, S ^e  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER SIZE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ECHOMAMMOGRAPHY; ECONOMIC ASPECT; ECONOMIC EVALUATION; HISTOPATHOLOGY; HUMAN; INFORMED CONSENT; INTERVENTION STUDY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PREOPERATIVE PERIOD; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REOPERATION; REVIEW; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CONTRAST MEDIA; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SATISFACTION;

EID: 75149166461     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta14010     Document Type: Review

References (92)

1. Del Turco MR, Mantellini P, Ciatto S, Bonardi R, Martinelli F, Lazzari B, et al. Full-field digital versus screen-film mammography: comparative accuracy in concurrent screening cohorts. AJR 2007;4:860-6.
2. Kaplan E, Yu E, Tripathy D. MRI patterns predict ability to perform breast conservation following neoadjuvant therapy for locally advanced breast cancer. Breast Cancer Res Treatment 2003;82(Suppl.):1-9.
3. Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol 2000;18:1668-75.
4. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455-61.
5. Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg 2002;184:383-93.
6. Tartter PI, Kaplan J, Bleiweiss I, Gajdos C, Kong A, Ahmed S, et al. Lumpectomy margins, reexcision, and local recurrence of breast cancer. Am J Surg 2000;179:81-5.
7. Van Goethem M, Schelfout K, Dijckmans L, Van Der Auwera JC, Weyler J, Verslegers I, et al. MR mammography in the pre-operative staging of breast cancer in patients with dense breast tissue: comparison with mammography and ultrasound. Eur Radiol 2004;14:8091-6.
8. Mariani L, Salvadori B, Marubini E, Conti AR, Rovini D, Cusumano F, et al. Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. Eur J Cancer 1998;34:1156-62.
9. Guinot JL, Roldan S, Maronas M, Tortajada I, Carrascosa M, Chust ML, et al. Breast-conservative surgery with close or positive margins: can the breast be preserved with high-dose-rate brachytherapy boost? Int J Radiation Oncol Biol Phys 2007;68:1381-7.
10. Karasawa K, Mitsumori M, Yamauchi C, Gomi K, Kataoka M, Uematsu T, et al. Treatment outcome of breast-conserving therapy in patients with positive or close resection margins: Japanese multi institute survey for radiation dose effect. Breast Cancer 2005;12:91-8.
11. Ramanah R, Pivot X, Sautiere JL, Maillet R, Riethmuller D. Predictors of re-excision for positive or close margins in breast-conservation therapy for pT1 tumors. Am J Surg 2008;195:770-4.
12. Zavagno G, Goldin E, Mencarelli R, Capitanio G, Del BP, Marconato R, et al. Role of resection margins in patients treated with breast conservation surgery. Cancer 2008; 112:1923-31.
13. NHS Breast Screening Programme and the Association of Breast Surgery. An audit of screen detected breast cancer for year of screening April 2006 to March 2007. Association of Breast Surgery at BASO conference, Birmingham, 11 June 2008.
14. Palka I, Kelemen G, Ormandi K, Lazar G, Nyari T, Thuro L, et al. Tumour characteristics in screen-detected and symptomatic cancers. Pathol Oncol Res 2008;14:161-7.
15. Harms SE, Flamig DP, Hesley KL, Meiches MD, Jensen RA, Evans WP, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993;187:493-501.
16. Davies PL, Staiger MJ, Harris KB, Ganott MA, Klementaviciene J, McCarthy KS, et al. Breast cancer measurements with magnetic resonance imaging, ultrasound and mammography. Breast Cancer Res Treatment 1996;37:1-9.
17. Ando Y, Fukatsu H, Ishigaki T, Endo T, Mikazaki M. Evaluation of breast cancer vascularity using MR mammography. In: Proceedings of the 5th ISMRM Meeting, Vancouver, Abstract 1045; April 1997.
18. Boetes C, Mus RD, Holland R, Barentsz JO, Strijk SP, Wobbes T, et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 1995;197:743-7.
19. Hata T, Takahashi H, Watanabe K, Takahashi M, Taguchi K, Itoh T, et al. Magnetic resonance imaging for preoperative evaluation of breast cancer: a comparative study with mammography and ultrasonography. J Am Coll Surg 2004;198:190-7.
20. Brix G, Schreiber W, Hoffmann U, Guckel F, Hawighorst H, Knopp MV. [Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography.] [German]. Radiologe 1997;37:470-80.
21. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-6.
22. Tofts PS, Berkowitz BA. Measurement of capillary permeability from the Gd enhancement curve: a comparison of bolus and constant infusion injection methods. J Magn Reson Imaging 1994;12:81-91.
23. American College of Radiology. Breast imaging reporting and data system atlas (BI-RADS atlas). Reston, VA: American College of Radiology; 2003.
24. Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology 2005;236:789-800.
25. Goto M, Ito H, Akazawa K, Kubota T, Kizu O, Yamada K, et al. Diagnosis of breast tumors by contrast-enhanced MR imaging: comparison between the diagnostic performance of dynamic enhancement patterns and morphologic features. J Magn Reson Imaging 2007;25:104-12.
26. Gibbs P, Liney GP, Lowry M, Kneeshaw PJ, Turnbull LW. Differentiation of benign and malignant sub-1 cm breast lesions using dynamic contrast enhanced MRI. Breast 2004;13:115-21.
27. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78.
28. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:8469-76.
29. Trecate G, Vergnaghi D, Manoukian S, Bergonzi S, Scaperrotta G, Marchesini M, et al. MRI in the early detection of breast cancer in women with high genetic risk. Tumori 2006;92:517-23.
30. Kneeshaw PJ, Lowry M, Manton D, Hubbard A, Drew PJ, Turnbull LW. Differentiation of benign from malignant breast disease associated with screening detected microcalcifications using dynamic contrast enhanced magnetic resonance imaging [see comment]. Breast 2006;15:293-8.
31. Bazzocchi M, Zuiani C, Panizza P, Del FC, Soldano F, Isola M, et al. Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial. AJR 2006;6:1723-32.
32. Kramer S, Schulz-Wendtland R, Hagedorn K, et al. Magnetic resonance imaging and its role in the diagnosis of multicentric breast cancer. Anticancer Res 1998;18:2163-4.
33. Balen FG, Hall-Craggs MA, Mumtaz H, Wilkinson I, Scheidau A. MRI of invasive lobular carcinoma of the breast. Proceedings of Radiology 1997, Birmingham, 19-21 May, p. 51. Br J Radiol 1997; 40(Suppl.).
34. Tan JE, Orel SG, Schnall MD, Schultz DJ, Solin LJ. Role of magnetic resonance imaging and magnetic resonance imaging: guided surgery in the evaluation of patients with early-stage breast cancer for breast conservation treatment. Am J Clin Oncol 1999;22:414-8.
35. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999;213:881-8.
36. Gilbert FJ, Cordiner CM, Affleck IR, Hood DB, Mathieson D, Walker LG. Breast screening: the psychological sequelae of false-positive recall in women with and without a family history of breast cancer. Eur J Cancer 1998;34:2010-14.
37. Sutton S, Saidi G, Bickler G, Hunter J. Does routine screening for breast cancer raise anxiety? Results from a three wave prospective study in England. J Epidemiol Community Health 1995;49:413-18.
38. Cockburn J, Staples M, Hurley SF, De LT. Psychological consequences of screening mammography. J Med Screening 1994;1:71-2.
39. Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological side effects of breast cancer screening. Health Psychol 1991;10:259-67.
40. Anderson J, Walker LG. Psychological aspects of MRI breast screening in women at high risk of breast cancer. In Warren RM, Coultard A, editors. Breast MRI in practice. London: Martin Dunitz; 2002.
41. Anderson J, Walker LG, Leach MO. Magnetic resonance imaging: an acceptable way of screening women with a family history of breast cancer. 27th Annual San Antonio Breast Cancer Symposium, 2004, p. 5014.
42. Brown J, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles RA, et al. Rationale for a National Multi-Centre Study of Magnetic Resonance Imaging (MRI) Screening in Women at Genetic Risk of Breast Cancer. Breast 2000;9:72-7.
43. Brown J, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles RA, et al. Protocol for magnetic resonance imaging screening in women at high genetic risk of breast cancer. Breast 2000;9:78-82.
44. van DS, Seynaeve C, Rijnsburger AJ, Duivenvoorden HJ, Essink-Bot ML, Tilanus-Linthorst MM, et al. Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer. Eur J Cancer 2005;41:1416-25.
45. Watson EK, Henderson BJ, Brett J, Bankhead C, Austoker J. The psychological impact of mammographic screening on women with a family history of breast cancer: a systematic review [review; 26 refs]. Psycho-Oncology 2005;14:939-48.
46. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
47. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997;15:974-86.
48. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
49. Brown GW, Rutter M. The measurement of family activities: a methodological study. Hum Relations 1966;19:241-63.
50. Walker LG, McKay E, Booth M, Crawford D, Davidson MI, Hunter D, et al. Multi-disciplinary assessment of pre-school handicapped children: pathways, professionals and parents. Aberdeen: University of Aberdeen; 1987.
51. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. J Clin Oncol 2007;25:2127-32.
52. Berg WA, Gilbreath PL. Multicentric and multifocal cancer: whole-breast US in preoperative evaluation. Radiology 2000;214:59-66.
53. Allen MJ, Thompson WD, Stuart RC, Gill PT, Walton EW, Karczenski K, et al. Management of non-palpable breast lesions detected mammographically. Br J Surg 1994;81:543-5.
54. Egan JF, Sayler CB, Goodman MJ. A technique for localizing occult breast lesions. CA Cancer J Clin 1976;26:32-7.
55. Norton LW, Zeligman BE, Pearlman NW. Accuracy and cost of needle localization breast biopsy. Arch Surg 1988;123:947-50.
56. Hermann G, Janus C, Lesnick G. Percutaneous localization of nonpalpable breast lesions. Breast 1983;1:4-6.
57. Jackman RJ, Marzoni FA, Jr. Needle-localized breast biopsy: why do we fail? Radiology 1997;204:677-84.
58. Fischer U, von HD, Vosshenrich R, Vieweg I, Grabbe E. [Signal characteristics of malignant and benign lesions in dynamic 2D-MRT of the breast] [German]. ROFO Fortschr Geb Rontgenstr Nuklearmed 1993;158:287- 92.
59. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989;170:681-6.
60. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999;211:101-10.
61. Euroqol webpage. URL: www euroqol org/ 2008
62. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
63. Kind P. The EuroQoL instrument: an index of health-related quality of life. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven; 1996.
64. Medical Research Council. MRC guidelines for good clinical practice in clinical trials. London: MRC; 1998.
65. BASO. An audit of screen detected breast cancer for year of screening April 1998 to May 1999. BASO Specialist Group Meeting, 2000. Included in the following report: www.cancerscreening.nhs.uk/ breastscreen/publications/ baso2003-2004.pdf.
66. Drummond MF, Sculpher MJ, O'Briend BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford Medical Publications; 2005.
67. Department of Health. NHS reference costs 2006-7. London: HMSO; 2006.
68. British Medical Association, The Royal Pharmaceutical Society of Great Britain. British National Formulary. URL: www BNF org 2007
69. Curtis L. Unit costs of health and social care 2007. Personal Social Services Research Unit, University of Kent; 2007.
70. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. York: University of York, Centre for Health Economics; 1995.
71. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Services Res Policy 2004;9:197-204.
72. Royston P. Multiple imputation of missing values. Stat J 2004;4:227-41.
73. Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
74. Kirkwood BR, Sterne JAC. Measurement error: assessment and implications. In Essential Medical Statistics. 2nd edn. Oxford: Blackwell Science; 2003, pp. 429-46.
75. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
76. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, et al. A combination of distribution-and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004;57:898-910.
77. Association of Breast Surgery @ BASO RCoSoE. Guidelines for the management of symptomatic breast disease. Eur J Surg Oncol 2005;31(Suppl. 1):1-21.
78. Liberman L. Breast MR imaging in assessing extent of disease [review; 54 refs]. Magn Reson Imaging Clin N Am 2006;14:339-49.
79. Smith RA. The evolving role of MRI in the detection and evaluation of breast cancer [comment]. N Engl J Med 2007;356:1362-4.
80. Sardanelli F, Giuseppetti GM, Panizza P, Bazzocchi M, Fausto A, Simonetti G, et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR 2004;183:1149-57.
81. Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007;356:1295-303.
82. Fox CH, Johnson FB, Whiting J, Roller PP. Formaldehyde fixation. J Histochem Cytochem 1985;33:845-53.
83. Pritt B, Tessitore JJ, Weaver DL, Blaszyk H. The effect of tissue fixation and processing on breast cancer size. Human Pathol 2005;36:756-60.
84. Yeap BH, Muniandy S, Lee SK, Sabaratnam S, Singh M. Specimen shrinkage and its influence on margin assessment in breast cancer. Asian J Surg 2007;30:183-7.
85. Kneeshaw PJ, Turnbull LW, Drew PJ. Role of magnetic resonance imaging in the diagnosis and single-stage surgical resection of invasive lobular carcinoma of the breast (Br J Surg 2002;89:1296-1301) [comment]. Br J Surg 2003;90:248.
86. Houssami N, Ciatto S, Macaskill P, Lord SJ, Warren RM, Dixon JM, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;38:419-25.
87. Montgomery DA, Krupa K, Jack WJ, Kerr GR, Kunkler IH, Thomas J, et al. Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 2007;96:1802-7.
88. Morrow M, Freedman G. A clinical oncology perspective on the use of breast MR. Magn Reson Imaging Clin N Am 2006;14:363-78.
89. Schmitz AC, Gianfelice D, Daniel BL, Th WP, van den Bosch MAAJ. Image-guided focused ultrasound ablation of breast cancer: current status and future directions. Eur Radiol 2008;18:1431-41.
90. NHS Cancer Screening Programmes and the Royal College of Pathologists. Pathology reporting of breast disease. Report no. 58. London: Department of Health; 2005.
91. Culyer AJ, McCabe C, Briggs A, Claxton K, Burton M, Akehurst R, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Services Res Policy 2007;12:56-8.
92. NICE. Guide to the methods of technology appraisal. London: NICE, 2008.